Review of 15 Clinical Trials Found Cannabinoids Most Promising for Spasticity, Tics, and Nerve Pain | Research

The takeaway

A review of 15 qualifying clinical trials found the strongest evidence for cannabinoids treating MS spasticity, Tourette's tics, and neuropathic pain, while results for cachexia, Parkinson's dyskinesia, and post-operative pain were negative.

Read this if you want a summary of what the early clinical trial evidence showed about which medical conditions cannabinoids might treat.

Only 15 qualifying clinical trials existed, and just 3 had more than 100 patients

What the researchers found

This review identified 15 independent, qualifying clinical trials (randomized, double-blind, placebo-controlled) of cannabinoid therapeutics published since 1997. Only three of the 15 had more than 100 patients.

Two large trials found cannabinoids significantly better than placebo for managing MS spasticity, though patients reported greater improvement than objective measures confirmed. Smaller trials showed significant objective improvement for tics in Tourette's disease and for neuropathic pain. A new non-psychotropic cannabinoid also showed analgesic activity for neuropathic pain.

No significant improvement was found for levodopa-induced dyskinesia in Parkinson's disease or post-operative pain. A large trial found no difference from active placebo for cachexia management. Quality of life assessments were made in only 3 of the 15 trials.

Why it matters

This review provides a snapshot of where cannabinoid research stood in the mid-2000s and helps distinguish conditions where evidence was emerging (spasticity, tics, neuropathic pain) from those where trials were negative (cachexia, Parkinson's, post-operative pain). The low number of large trials highlights how early clinical cannabinoid research was at this point.

The numbers in context

15 qualifying clinical trials identified. Only 3 had more than 100 patients. Quality of life assessed in only 3 of 15 trials. Positive findings: MS spasticity (2 large trials), Tourette's tics, neuropathic pain. Negative findings: Parkinson's dyskinesia, post-operative pain, cachexia.

How the study worked

Literature review searching publications since 1997 using terms including cannabinoid, marijuana, THC, and various medical conditions. Qualifying studies were randomized, double-blind, and placebo-controlled. Selected open-label studies and surveys were also discussed. Fifteen qualifying clinical trials were identified.

What this study cannot tell us

Only 15 qualifying trials existed, most with small sample sizes. The review was limited to studies since 1997. Self-reported improvement in MS trials exceeded objective measures, raising questions about placebo effects. The distinction between different cannabinoid formulations and delivery methods was not always clear.

How to read the evidence

Narrative review of randomized controlled trials. Provides a useful overview but does not use systematic review methodology.

When this study was published

Published in 2005. The number of cannabinoid clinical trials has grown substantially since then. Several conditions discussed here now have much larger evidence bases.

The bigger picture

By 2005, the evidence base for medical cannabinoids was still quite thin. This review captures the transition period when researchers were moving from anecdotal and survey evidence toward rigorous clinical trials. Many of the conditions identified as promising here became the focus of larger subsequent trials.

Questions still open

Why do MS patients report greater improvement than objective measures confirm? Would larger, more rigorously designed trials confirm the positive findings for tics and neuropathic pain?

Common questions

What conditions had the strongest evidence for cannabinoid treatment?

MS spasticity had the strongest support from two large trials. Tourette's tics and neuropathic pain also showed significant improvement in smaller trials. Cachexia, Parkinson's dyskinesia, and post-operative pain trials were negative.

Why were there so few clinical trials?

Cannabinoid clinical research was still in early stages in 2005. Legal restrictions, funding challenges, and the need for standardized pharmaceutical-grade cannabinoid preparations all limited the pace of clinical trials.

Read the original research

Recent developments in the therapeutic potential of cannabinoids.

Puerto Rico health sciences journal, 24(1), 19-26

View on PubMed ↗

Citation

Corey, Susan. (2005). Recent developments in the therapeutic potential of cannabinoids.. Puerto Rico health sciences journal, 24(1), 19-26.